AFRICA MIDDLE EAST
This region represents the single largest revenue contributor in the Commercial Pharmaceuticals segment, with revenues predominantly from Regional Brands. Aspen supplies well-established local brands, as well as internationally recognised medicines across multiple countries in the region, supported by commercial and sales employees. Extensive and differentiated manufacturing capabilities including high potency and hormonal solids, vaccines and other state-of-the-art sterile capabilities exist at one of the Group’s primary manufacturing sites in Gqeberha, South Africa. This primary site is complemented by five regional sites across the continent.
Kingdom of Saudi Arabia
|Eltroxin||Thyroid hormone replacement|
NUMBER OF PERMANENT EMPLOYEES
Number of products launched:
Number of product recalls:
Average staff turnover:
Number of work-related fatalities:
|Total Commercial Pharmaceuticals||8 570||8 319||3|
|Regional Brands||8 057||7 870||2|
|Sterile Focus Brands||513||449||14|
|Total||9 523||8 999||6|
Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.
- The South African private pharmaceutical sector was valued at R49,8 billion MAT* for the period ended July 2021.
- In South Africa, four out of the top 15 brands in the private sector were Aspen products.
- Aspen is ranked as the number one pharmaceutical company in the South African private sector with an 11,1% share by value.
- Middle East and North Africa’s (“MENA”) growth in pharmaceutical industry sales will mainly be driven by Egypt and Turkey over the next three years.
- Pharmaceutical industry sales in the MENA region are expected to grow in USD by value at 4,6% compound annual growth rate (“CAGR”) between 2021 and 2024.
Source: IQVIA, IQVIA Midas 2021 and Market Prognosis Global. South Africa and Middle East and North Africa only.
Sub-Saharan Africa (“SSA”) not covered by IQVIA
*MAT = Moving annual total